Roivant Sciences Files 8-K on Shareholder Votes & Financials
Ticker: ROIV · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1635088
Sentiment: neutral
Topics: regulatory-filing, corporate-governance, financials
TL;DR
Roivant Sciences filed an 8-K on 9/11/25 covering shareholder votes and financials. Offices in London.
AI Summary
Roivant Sciences Ltd. filed an 8-K on September 11, 2025, reporting on matters submitted to a vote of security holders and financial statements. The filing details their principal executive offices located at 7th Floor, 50 Broadway, London, SW1H 0DB, United Kingdom, and provides their contact number as +44 207 400-3347.
Why It Matters
This filing provides an update on Roivant Sciences' corporate governance and financial reporting, which is important for investors to track company activities and compliance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing detailing corporate actions and financial information, not indicating any immediate operational or financial distress.
Key Players & Entities
- Roivant Sciences Ltd. (company) — Registrant
- September 10, 2025 (date) — Earliest event reported
- September 11, 2025 (date) — Date of report
- 7th Floor, 50 Broadway, London, SW1H 0DB, United Kingdom (location) — Principal executive offices
- +44 207 400-3347 (phone_number) — Registrant's Telephone Number
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates 'Submission of Matters to a Vote of Security Holders' as an item, but the specific details of these matters are not elaborated in the provided text.
What financial statements are included in this filing?
The filing lists 'Financial Statements and Exhibits' as an item, but the specific financial statements are not detailed in the provided text.
When was the earliest event reported in this 8-K?
The earliest event reported was on September 10, 2025.
Where are Roivant Sciences Ltd.'s principal executive offices located?
Roivant Sciences Ltd.'s principal executive offices are located at 7th Floor, 50 Broadway, London, SW1H 0DB, United Kingdom.
What is the registrant's telephone number?
The registrant's telephone number is +44 207 400-3347.
Filing Stats: 686 words · 3 min read · ~2 pages · Grade level 11.3 · Accepted 2025-09-11 17:00:42
Key Financial Figures
- $0.0000000341740141 — nge on which registered Common Shares, $0.0000000341740141 per share ROIV The Nasdaq Global Se
Filing Documents
- ef20055421_8k.htm (8-K) — 39KB
- 0001140361-25-034711.txt ( ) — 165KB
- roiv-20250910.xsd (EX-101.SCH) — 4KB
- roiv-20250910_lab.xml (EX-101.LAB) — 21KB
- roiv-20250910_pre.xml (EX-101.PRE) — 16KB
- ef20055421_8k_htm.xml (XML) — 4KB
07
Item 5.07. Submission of Matters to a Vote of Security Holders. On September 10, 2025, Roivant Sciences Ltd. (the "Company") held its 2025 Annual General Meeting of Shareholders. At that meeting, the shareholders considered and acted upon three proposals as described in more detail in the Company's Proxy Statement. Of 682,519,374 common shares outstanding and entitled to vote as of the close of business on the record date for the meeting, July 17, 2025, the holders of record of 628,673,675 common shares were present at the meeting either in person or by proxy. All proposals on the agenda were approved by the shareholders. Below are the final voting results. (1) Shareholders re-elected the individuals named below to serve as Class I directors of the Company, to hold office until the date of the annual general meeting of shareholders following the fiscal year ending March 31, 2028, and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal. Election of each director required approval by a plurality of the votes cast. Nominee For Withheld Broker Non-Votes Matthew Gline 430,013,727 154,432,135 44,227,813 Keith Manchester 412,869,513 171,576,349 44,227,813 Melissa Epperly 429,542,705 154,903,157 44,227,813 (2) Shareholders ratified the appointment of Ernst & Young LLP ("EY") to serve as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2026, and to appoint EY as the Company's auditor for statutory purposes under the Bermuda Companies Act 1981, as amended, for the fiscal year ending March 31, 2026. Ratification required a simple majority of the votes cast. For 628,068,956 Against 479,264 Abstain 125,455 (3) Shareholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, including the compensation tables and related narrative disclosures. For
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROIVANT SCIENCES LTD. Date: September 11, 2025 By: /s/ Keyur Parekh Name: Keyur Parekh Title: Authorized Signatory